Ondansetron, a New Antiemetic Therapy for Oncology

References

• Seigel L J, Longo DL. The control of chemotherapy-induced emesis. Ann Intern Med 1981; 95: 352–359
   PubMed Web of Science ®Google Scholar
• Marin J, Ibanez M C, Arribas S. Therapeutic management of nausea and vomiting. Gen Pharmacol 1990; 21: 1–10
   PubMedGoogle Scholar
• Isselbacher KJ. Anorexia, nausea and vomiting. Harrison's principles of internal medicine, AS Brawnwald, KJ Isselbacher, RJ Petersdorf, JD Wilson, JB Martin, AS Fauci. McGraw Hill, New York, 173–175
   Google Scholar
• Borison H L, Wang SC. Physiology and pharmacology of vomiting. Pharmacol Rev 1953; 5: 193–230
   PubMed Web of Science ®Google Scholar
• Wang SC. Emetic and antiemetic drugs. Physiological pharma, WS Root, FG Hofmann. Academic Press, New York 1965; Vol. II: 255–328
   Google Scholar
• Triozzi P L, Laslo J. Optimum management of nausea and vomiting in cancer chemotherapy. Drugs 1987; 334: 136–149
   Google Scholar
• Gralla R J, Itri L M, Pisko S E, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperacine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981; 305: 905–909
   PubMed Web of Science ®Google Scholar
• Gaddum J H, Picarelli ZP. Two kinds of tryptamine receptors. Br J Pharmacol 1957; 12: 323–328
   PubMed Web of Science ®Google Scholar
• Bradley P B, Engel G, Feniuk W. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 1986; 25: 563–576
   PubMed Web of Science ®Google Scholar
• Göthert M, Schlicker E. Identification and classification of 5-HT, receptor subtypes. J Cardiovasc Pharmacol 1990; 15: S1–S7, suppl 7
   PubMedGoogle Scholar
• Bobker D H, Williams JT. Ion conductances affected by 5-HT receptor subtypes in mammalian neurons. TINS 1990; 13: 169–173
   PubMedGoogle Scholar
• Kilpatrick G J, Jones B J, Tylers MB. The identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 1987; 330: 746–748
   PubMed Web of Science ®Google Scholar
• Richardson B P, Engel G, Donatsch P, Stadler PA. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 1985; 316: 36–44
   Google Scholar
• Kilpatrick G J, Jones B J, Tyers MB. The distribution of specific GR 65630 binding to the brains of several species. Characterisation of binding to rat area postrema and vagus nerve. Eur J Pharmacol 1989; 159: 157–164
   PubMedGoogle Scholar
• Bertaccini G. Tissue 5-hydroxytryptamine and urinary 5-hydroxyindoleacetic acid after partial or total removal of the gastro-intestinal tract in the rat. J Physiol (Lond) 1960; 153: 239–249
   Google Scholar
• Feldberg W, Toh CC. Distribution of 5-hydroxytryptamine (serotonin, enteramine) in the wall of the digestive tract. J Physiol (Lond) 1953; 119: 352–362
   Google Scholar
• Resnick R H, Gray SJ. Distribution of serotonin (5-hydroxytryptamine) in the human gastrointestinal tract. Gastroenterology 1961; 41: 119–121
   PubMed Web of Science ®Google Scholar
• Robinson R G, Gershon MD. Synthesis and uptake of 5-hydroxytryptamine by the myenteric plexus of the guinea-pig ileum: a histochemical study. J Pharmacol Exp Ther 1971; 178: 311–324
   PubMed Web of Science ®Google Scholar
• Cubeddu L X, Hoffman I S, Fuenmayor N T, Finn AL. Efficacy of ondansetron (GR38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990; 322: 810–816
   PubMed Web of Science ®Google Scholar
• Tyers M B, Bunce K T, Humphrey P PA. Pharmacological and anti-emetic properties of ondansetron. Eur J Cancer Clin Oncol 1989; 25: S15–S19, suppl 1
   PubMedGoogle Scholar
• Costall B, Domeney A M, Gunning S J, Naylor R J, Tattershall F D, Tyers MB. GR38032F, a potent and novel inhibitor of cisplatin-induced emesis in the ferret. Br J Pharmacol 1987; 90: 90P
   Google Scholar
• Stables R, Andrews P LR, Bailey H E, et al. Antiemetic properties of the 5-HT,-receptor antagonist, GR38022F. Cancer Treat Rev 1987; 14: 333–336
   PubMed Web of Science ®Google Scholar
• Andrews P LR, Bailey H E, Hawthorn J, Stables R, Tyers MB. GR38032F, a novel 5-HT, antagonist, can abolish emesis induced by cyclophosphamide or radiation in the ferret. Br J Pharmacol 1988; 91: 417P
   Google Scholar
• Butler A, Hill JM, Ireland SJ, Jordan CC, Tyers MB. Pharmacological properties of GR38032F. a novel antagonist at 5-HT, receptors. Br J Pharmacol 1988; 94: 397–412
   PubMed Web of Science ®Google Scholar
• Blackwell C P, Harding SM. The clinical pharmacology of ondansetron. Eur J Cancer Clin Oncol 1989; 25: S21–S24, suppl 1
   PubMedGoogle Scholar
• Marty M. Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting. Eur J Cancer Clin Oncol 1989; 25: S41–S45, suppl 1
   Google Scholar
• Einhorn L H, Nagy C, Werner K, Finn AL. Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol 1990; 8: 731–735
   PubMed Web of Science ®Google Scholar
• Marty M, Pouillart P, Scholl S, et al. Comparison of the 5-hydroxytryptamine-, (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclo-pramide in the control of cisplatin-induced emesis. N Engl J Med 1990; 3222: 816–821
   Google Scholar
• Schmoll HJ. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes. Eur J Cancer Clin Oncol 1989; 25: S35–S39, suppl 1
   PubMedGoogle Scholar
• Kaasa S, Kvaloy S., Dicato MA., et al. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. Eur J Cancer 1990; 26: 311–314
   PubMed Web of Science ®Google Scholar
• Priestman TJ. Clinical studies with ondansetron in the control of radiation-induced emesis. Eur J Cancer Clin Oncol 1989; 25: S29–S33, suppl 1
   PubMedGoogle Scholar
• Smith RN. Safety of ondansetron. Eur J Cancer Clin Oncol 1989; 25: S47–S50, suppl 1
   PubMedGoogle Scholar
• Tucker M L, Jackson M R, Scales M DC, Spurling N W, Tweats D J, Capel-Edwards K. Ondansetron: pre-clinical safety evaluation. Eur J Cancer Clin Oncol, 25: S79–S93, suppl 1
   Google Scholar
• Talley NJ, Phillips SF, Miller LJ, Haddad A. A specific 5-HT, antagonists delays colonic transit and inhibits postprandial neurotensin (NT) release. Gastroenterology 1988; 95: 116
   Google Scholar
• Hawthorn J, Cunningham D. Dexamethasone can potentiate the anti-emetic action of a 5HT, receptor antagonist on cyclophosphamide induced vomiting in the ferret. Br J Cancer 1990; 61: 56–60
   PubMed Web of Science ®Google Scholar
• Tonato M. Satellite symposium Zophran (ondansetron), Abstract book. Glaxo, Hamburg 17 August, 1990; 21–23
   Google Scholar
• Grunberg SM. Making chemotherapy easier. N Engl J Med 1990; 322: 846–848
   PubMed Web of Science ®Google Scholar
• Leonard R CF, Soukop M. Anti-emetics and cancer chemotherapy. Br J Cancer 1990; 61: 349–350
   PubMedGoogle Scholar